Clinical trials: Recurrent Pregnancy Loss
Recurrent Miscarriage
Walking and Dietary Modification for Recurrent Early Miscarriages
This study is part of a big one aiming to evaluate how lifestyle interventions during pregnancy affect obstetric results, neonatal metabolism and the intelligence of the offspring (study not yet completed).
- Trial name
- W&D (NCT03023137)
- Testing
- Walking & dietary modification
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- Hospital dos Servidores do Estado do Rio de Janeiro
Miscarriage, Recurrent, Abortion, Habitual
Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the…
- Trial name
- NCT00606905
- Testing
- Gamimune N or Gamunex 10%, normal saline
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Chicago
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Recurrent Pregnancy Loss, Unexplained Infertility
Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
The purpose of this study is to determine if patients with recurrent pregnancy loss or unexplained infertility have an altered uterine gene expression or uterine microbiome (micro-organism composition) during the window of embryo…
- Trial name
- NCT03401918
- Testing
- Uterine ERA and microbiome testing, Oral antibiotics and vaginal probiotics
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hyperinsulinemia, Miscarriages
Maternal Lifestyle and Neonatal Hypoglycemia
tPA has a pivotal role in placentation, mediationg activation of growth factors, such as vascular endothelial growth factor and brain-derived neurotrophic factor, degradation of extracellular matrix and basement membrane…
- Conditions
- Hyperinsulinemia, Miscarriages, Pregnancy, Sedentary Lifestyle
- Trial name
- NCT01409382
- Testing
- Daily brisk walking plus a carbohydrate-restricted diet
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- Hospital dos Servidores do Estado do Rio de Janeiro
Cachexia, Squamous Cell Carcinoma
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard…
- Trial name
- NCT00878995
- Testing
- Testosterone Enanthate 100 MG/ML
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Recurrent Abortion
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with…
- Trial name
- NCT01051778
- Testing
- enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Recurrent Miscarriage, Spontaneous Abortion
Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)
The present study is based on the hypothesis, that recurrent pregnancy loss (RPL) is associated with abnormal plasma mannose binding lectin (p-MBL) level.
- Conditions
- Recurrent Miscarriage, Spontaneous Abortion, Mannose-Binding Lectin Deficiency, Habitual Abortion
- Trial name
- NCT04017754
- Where
- Denmark
- Volunteers
- 452 people
- Sponsor
- Aalborg University Hospital
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02059265
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 227 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)